New imaging agent may reveal hidden prostate cancer recurrence

NCT ID NCT05588128

Recruiting now Diagnosis Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 6 times

Summary

This study is testing whether a radioactive tracer called 18F-DCFPyL, used during a PET/CT scan, can better detect where prostate cancer has returned in men whose PSA levels are rising after initial treatment. About 350 men will be followed for up to 5 years with regular scans and blood tests. The goal is to see if this imaging method can find cancer that standard scans miss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-DCFPyL (a radioactive tracer used for PET imaging)
What this could lead to: If successful, this could lead to a more accurate way to find recurrent prostate cancer, helping doctors decide on the best treatment sooner.
What could go wrong: This is an observational study, not a treatment trial. The tracer may not detect all cancer sites, and results may not change patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOCHEMICALLY RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOCHEMICALLY RECURRENT PROSTATE CANCER

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.